Somaye Barashki - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Atena Aghaei - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Seyed Rasoul Zakavi - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Fatemeh Mohammad Bagherpour - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Susan Shafiei - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Hadis Mohammadzadeh Kosari - Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Introduction: The present study aims to assess pre-thyroidectomy thyroid hormone disturbances among patients suffering from differentiated thyroid carcinoma (DTC).Methods: This retrospective study was performed from September ۲۰۲۰ to March ۲۰۲۱. We analyzed the hospital files of ۷۱۰ patients with DTC who underwent thyroidectomy and referred to nuclear medicine department from April ۲۰۱۳ to September ۲۰۱۹. Demographics, TNM stage, pre-surgery thyroid function tests, time-interval to achieve a complete response, recurrence rate, one-year response, final response, and the need for alternative treatment modalities were extracted. Then, we analyzed the potential association of pre-surgery TSH levels with the initial disease stage and treatment response. Chi-Square, Analysis-of-variance, and Kruskal-Wallis tests were used where appropriate.Results: The mean age of participants was ۴۰.۳۹ ± ۱۳.۸۵ years. History of Hashimoto's disease was detected in ۱۳۰ (۱۸.۳%) patients. Multi-focal DTC was found in ۲۲۱ (۳۱.۲%) patients. Lymph node involvement was significantly higher among men (p = ۰.۰۰۱). Men also had significantly higher thyroglobulin levels (p = ۰.۰۲۵). No statistically significant association was found between pre-surgery thyroid function status and TNM stage or multifocality of the malignancy. Baseline thyroid function tests also did not show a statistically significant relationship with thyroglobulin, anti-thyroglobulin antibody, time to first excellent response, and follow-up duration.Conclusion: Baseline thyroid function status may not change the outcome of DTC. It could also be plausible that thyroid dysfunction before surgery would not increase invasiveness nor impact the treatment-response of the tumor compared to euthyroid patients.

Thyroid cancer, Prevalence, Thyroid stimulating hormone, Differentiated thyroid cancer